Table 1.
No. | API | Mechanisms and Effects | Formulations | Ref. |
---|---|---|---|---|
1. | Erythromycin -topical- |
Antibacterial Bacterial resistance may occur |
Solution with zinc acetate Gel with isotretinoin |
[105,106,107,108] |
2. | Zinc acetate -topical- |
Anti-inflammatory Antioxidant |
Solution with erythromycin | [109] |
3. | Clindamycin phosphate -topical- |
Antibacterial Bacterial resistance may occur |
Gel, 1% Gel with tretinoin, 1.2%/0.025% Gel with nicotinamide 1%/4% Gel with benzoyl peroxide 1%/2.5% |
[105] [110,111,112,113] |
4. | Nicotinamide -topical- |
Anti-inflammatory Moisturizer |
Gel 4%/5% alone or with clindamycin | [111,112] |
5. | Metronidazole -topical- |
Antibacterial Anti-inflammatory |
Cream, 1% Gel, 1%, 2% |
[114,115] |
6. | Ivermectin -topical- |
Anti-parasitic Anti-inflammatory |
Cream, 1% | [116] |
7. | Doxycycline -systemic- |
Antibacterial Bacterial resistance may occur |
Capsules, 100 mg | [117] |
8. | Minocycline -systemic- -topical- |
Antibacterial Hepatic affection, vestibular events, autoimmune skin disorders may occur Induce photosensitivity |
Tablets, 100 mg Foam, 4% |
[117,118] |
9. | Tetracycline -systemic- -topical- |
Antibacterial Affected oral absorption when is administered with food Induce photosensitivity |
Capsules, 250 mg Ointment, 3% |
[119] [120,121] |
10. | Cotrimoxazole -systemic- |
Antibacterial Off-label use Just in refractar cases |
Tablets, 400 mg/80 mg, 800 mg/160 mg |
[122] |
11. | Azelaic acid -topical- |
Anti-inflammatory, antioxidant Increased erythema may occur Induce photosensitivity |
Cream, 20% Gel, 15% Foam, 15% |
[123] |
12. | Benzoyl peroxide -topical- |
Antibacterial Erythema, burning sensations, dryness may occur Induce photosensitivity |
Gel, alone or with clindamycin | [113] |
13. | Salicylic acid -topical- |
Anti-inflammatory Keratoplastic Erythema, dryness may occur |
Cosmeceuticals Associated with topical moisturizers Gel, 2% |
[124,125,126] |
14. | Isotretinoin -systemic- -topical- |
Equilibration of desquamation process, by targeting retinoic acid receptors (RAR) (α, β and γ) Anti-inflammatory Erythema, dryness may occur |
Capsules 10–40 mg Gel, 0.05% and 0.1% with erythromycin 4% |
[93] [127,128] |
15. | Tretinoin -topical- |
Equilibration of desquamation process, by targeting retinoic acid receptors RAR (α, β and γ) Anti-inflammatory Erythema, dryness may occur |
Cream Gel formulation with clindamycin Concentration domain 0.01–0.1% |
[127,129] |
16. | Adapalene -topical- |
Equilibration of desquamation process, by targeting retinoic acid receptors RAR (α, β and γ) Anti-inflammatory Erythema, dryness may occur |
Gel with benzoyl peroxide 0.1/2.5% and 0.3/2.5% |
[127,129] |
17. | Tazarotene -topical- |
Equilibration of desquamation process, by targeting retinoic acid receptors RAR (α, β and γ), selectively on β and γ receptors Anti-inflammatory Erythema, dryness may occur |
Cream Gel Foam, 0.1% |
[127,130] |
18. | Trifarotene -topical- |
Equilibration of desquamation process, by targeting RAR γ Anti-inflammatory, comedolytic |
Cream, 0.005% | [131] |
19. | Cortexolone 17α-propionate -topical- |
Antiandrogen Anti-inflammatory |
Cream, 1% | [132] |
20. | Spironolactone -systemic- |
Antiandrogen Only women recommended |
Tablets, 25–200 mg |
[133] |
21. | Cyproterone -systemic- |
Antiandrogen Headache, edema, hepatic affection, menstrual cycle modification may occur Last line therapy |
Tablets, 50–100 mg or combined with ethinylestradiol 2 mg/0.035 mg |
[134] |
22. | Dapsone -systemic- -topical- |
Antibacterial High tolerability |
Tablets, 300 mg Gel, 5%, 7.5% |
[135,136] |